Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer (Q24234155)

inferred from title

author

Holger Jens Schünemann

8

0 references

Maddalena Barba

4

0 references

Francesca Sperati

5

0 references

Irene Terrenato

6

0 references

Elie A Akl

1

0 references

Paola Muti

7

object named as

Paola Muti

0 references

Srinivasa Rao Vasireddi

2

object named as

Srinivasa Rao Vasireddi

0 references

Sameer Gunukula

Cochrane Database of Systematic Reviews

3

object named as

Sameer Gunukula

0 references

publication date

16 February 2011

0 references

published in

0 references

cites work

Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Low-Molecular-Weight Heparin in the Treatment of Patients with Venous Thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Venous thromboembolism in pediatrics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Low-molecular-weight heparin for the treatment of venous thrombosis in patients with adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Successful management of acute pulmonary embolism after surgery for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Deep vein thrombosis of the leg. Is there a "high risk" group?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Home versus in-patient treatment for deep vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Prognosis of Cancers Associated with Venous Thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

7 January 2021

Nontraumatic vascular emergencies: imaging and intervention in acute venous occlusion.

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

7 January 2021

Therapeutic and clinical course of deep vein thrombosis

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

7 January 2021

Heparin in the Treatment of Hemorrhagic Diathesis Associated with Prostatic Carcinoma

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

7 January 2021

Are patients with cancer receiving adequate treatment for thrombosis? Results from FRONTLINE

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

7 January 2021

Cancer-associated thrombosis

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

7 January 2021

Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

7 January 2021

How I treat venous thromboembolism in patients with cancer

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

7 January 2021

Venous thromboembolism in malignancy

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

7 January 2021

Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

7 January 2021

Heparin and CXCL12 dimerization

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006649.PUB3

7 January 2021